Armstrong Advisory Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Armstrong Advisory Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.6K	Hold	150	–	–	﹤0.01%	875
2026 Q1	$1.86K	Hold	150	–	–	﹤0.01%	879
2025 Q4	$1.89K	Hold	150	–	–	﹤0.01%	870
2025 Q3	$1.5K	Hold	150	–	–	﹤0.01%	880
2025 Q2	$1.21K	Buy	+150	New	+$1.13K	﹤0.01%	865

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Armstrong Advisory Group's AMRX Position: Q2 2026 in Review

Armstrong Advisory Group held its Amneal Pharmaceuticals (AMRX) position steady in Q2 2026 at 150 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #875.

Armstrong Advisory Group first reported a position in AMRX in Q2 2025 and has held it in 5 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Armstrong Advisory Group held 150 shares of Amneal Pharmaceuticals worth $2.6K as of Q2 2026.
Armstrong Advisory Group left its Amneal Pharmaceuticals share count unchanged in Q2 2026.
Amneal Pharmaceuticals made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #875 holding.
Armstrong Advisory Group first reported a position in Amneal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.